Preventing Restenosis of Cerebral Arterial Stents with Aggrenox "PRCASA"

Recruiting

Phase N/A Results N/A

Summary of Purpose

To evaluate the effect of Aggrenox, in combination with standard medical therapy, on the re-narrowing or "restenosis" of cerebrovascular stents seen at six months.

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 2 April 2009.

Unavailable Unavailable Unavailable Unavailable Unavailable Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics

Interventions

Sponsors

  • Boehringer Ingelheim Ingelheim, Germany

Trial Design

Randomized, open-label, single-center trial.

Contacts

  • Joey English, M.D. Ph.D. University of California, San Francisco 505 Parnassus Avenue San Francisco, CA 94143-0114

    joeyenglish@gmail.com